5th Edition of International Conference on Tissue Engineering and Regenerative Medicine, 5th Edition of Euro-Global Conference on Biotechnology and Bioengineering 2025 (2025), Seite 121-122 1 Online-Ressource
von Bastian Schrader ; Friedrich Lorenz ; Armin Weers ; Matteo Scorcelletti ; Stephan Lüders ; Bernhard Vaske ; Sandra Garstecki ; Joachim Schrader ; Albrecht Elsässer
von Bastian Schrader ; Armin Weers ; Burkhard Garmann ; Stephan Lüders ; Matteo Scorcelletti ; Bernhard Vaske ; Paul Meyer ; Eugen Gehlenborg ; Sandra Garstecki ; Joachim Schrader ; Albrecht Elsässer
von Clemens Enno Eckel ; Fadi Al-Rashid ; Sophie Bargon ; Judith Schlüter ; Dagmar Beate Sötemann ; Albrecht Elsässer ; Johannes Blumenstein ; Helge Möllmann ; Christina Grothusen
von Hans-Josef Feistritzer ; Alexander Jobs ; Uwe Zeymer ; Steffen Schneider ; Philipp Lauten ; Miroslaw Ferenc ; Maren Weferling ; Regine Brinkmann ; Sebastian Winkler ; Ulf Landmesser ; Tobias Daniel Trippel ; Christoph Stellbrink ; Harm Wienbergen ; Georg Fürnau ; Helge Möllmann ; Axel Linke ; Christian Jung ; Alexander Lauten ; Stephan Achenbach ; Tienush Rassaf ; Thomas Schmitz ; Sebastian Cremer ; Christoph Olivier ; Volker Schächinger ; Samuel Tobias Sossalla ; Karl Toischer ; Christian Templin ; Daniel Sedding ; Peter Clemmensen ; Eike Philipp Tigges ; Felix Meincke ; Haitham Abu Sharar ; Saarraaken Kulenthiran ; Paul Christian Schulze ; Claudius Jacobshagen ; Derk Frank ; Stephan Baldus ; Ralf Lehmann ; Christian Spies ; Norbert Klein ; Ingo Eitel ; Ralf Zahn ; Alexander Schmeisser ; Tommaso Gori ; Philipp Lurz ; Ibrahim Akın ; Georgios Chatzis ; Konstantinos Rizas ; Thorsten Keßler ; Fadil Ademaj ; Albrecht Elsässer ; Lars Siegfried Maier ; Alper Öner ; Alexander Staudt ; Nikos Werner ; Tobias Geisler ; Mirjam Keßler ; Markus Ferrari ; Melchior Seyfarth ; Peter Johann Nordbeck ; Sebastian Ewen ; Christian Bietau ; Arash Haghikia ; Sebastian J. Reinstadler ; Alexander Geppert ; Nadine Hösler ; Gabor Toth-Gayor ; Björn Ulrich Nicolas Billmann ; Ramon Tschierschke ; Christian Schmidt ; Stephan Fichtlscherer ; Holger Thiele
Online verfügbar: 8. April 2025, Artikelversion: 1. Mai 2025 ; Gesehen am 19.08.2025
Background - Multivessel coronary artery disease (CAD) is present in 30% to 70% of patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI) depending on varying age and risk profiles. In contrast to the STEMI cohort, there is only limited scientific evidence derived from randomized controlled trials directing the general decision for or against complete revascularization in the NSTEMI population. - Primary hypothesis - The COMPLETE-NSTEMI trial aims to investigate whether multivessel percutaneous coronary intervention (PCI) is superior over culprit-lesion only PCI in patients with NSTEMI and multivessel CAD. - Design - COMPLETE-NSTEMI is a prospective, randomized, controlled, multicenter, parallel group, open-label trial. It will enroll 3390 NSTEMI patients with multivessel CAD at 65 to 70 sites in Germany and Austria. Patients will be randomized 1:1 to either complete revascularization with PCI or culprit lesion-only PCI. - Endpoints - The primary efficacy endpoint is a composite of cardiovascular death or rehospitalization for nonfatal myocardial infarction during follow-up. The trial is event-driven and will be stopped as soon as 578 primary endpoint events and a minimal follow-up duration of 12 months for each patient are reached. - Current status - The first patient was enrolled at October 27, 2023. By April 2025, 51 sites have been activated and >500 patients have been randomized. Completion of recruitment is expected for the first half of 2027. The final results of the primary endpoint are expected in 2028. - Outlook - COMPLETE NSTEMI will be the first dedicated trial to answer the question about the optimal revascularization strategy in patients with NSTEMI and multivessel CAD. - Trial registration: ClinicalTrials.gov - NCT05786131
American heart journal Amsterdam [u.a.] : Elsevier, 1925 287(2025), Seite 94-106 Online-Ressource
von Clemens Enno Eckel ; Won-Keun Kim ; Judith Schlüter ; Matthias Renker ; Sophie Bargon ; Christina Grothusen ; Albrecht Elsässer ; Guido Dohmen ; Yeong-Hoon Choi ; Efstratios I. Charitos ; Christian W. Hamm ; Samuel Sossalla ; Helge Möllmann ; Johannes Blumenstein
von Clemens Enno Eckel ; Won-Keun Kim ; Dagmar Sötemann ; Christina Grothusen ; Vedat Tiyerili ; Guido Dohmen ; Matthias Renker ; Efstratios I. Charitos ; Christian W. Hamm ; Yeong-Hoon Choi ; Albrecht Elsässer ; Helge Möllmann ; Johannes Blumenstein
Erstmals online veröffentlicht: 15. Mai 2024 ; Gesehen am 17.12.2024
Aim - Out-of-hospital cardiac arrest (OHCA) is a major health concern in Western societies. Poor outcome after OHCA is determined by the extent of hypoxic-ischemic encephalopathy (HIE). Dysregulation of iron metabolism has prognostic relevance in patients with ischemic stroke and sepsis. The aim of this study was to determine whether serum iron parameters help to estimate outcomes after OHCA. - Methods - In this prospective single-center study, 70 adult OHCA patients were analyzed. Serum ferritin, iron, transferrin (TRF), and TRF saturation (TRFS) were measured in blood samples drawn on day 0 (admission), day 2, day 4, and 6 months after the return of spontaneous circulation (ROSC). The association of 4 iron parameters with in-hospital mortality, neurological outcome (cerebral performance category [CPC]), and HIE was investigated by receiver operating characteristics and multivariate regression analyses. - Results - OHCA subjects displayed significantly increased serum ferritin levels on day 0 and lowered iron, TRF, and TRFS on days 2 and 4 after ROSC, as compared to concentrations measured at a 6-month follow-up. Iron parameters were not associated with in-hospital mortality or neurological outcomes according to the CPC. Ferritin on admission was an independent predictor of features of HIE on cranial computed tomography and death due to HIE. - Conclusion - OHCA is associated with alterations in iron metabolism that persist for several days after ROSC. Ferritin on admission can help to predict HIE.
Journal of intensive care medicine Thousand Oaks, Calif. [u.a.] : Sage Science Press, 1986 39(2024), 11 vom: Nov., Seite 1120-1130 Online-Ressource
